Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Gabriele Martelli

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Tiziana Triulzi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Caterina Sposetti

Dana-Farber Cancer Institute

UNITED STATES

View details

Filippo Guglielmo Maria de Braud

Professor

Università di Milano

ITALY

View details

Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Mattia Rediti

Université libre de Bruxelles (ULB)

BELGIUM

View details

Kjersti Flatmark

Oslo University Hospital

NORWAY

View details

Giovanni Fucà

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Paolo Manca

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antonia Martinetti

Research Interests

Explore related searches

Contact this professor

Articles (10)

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.

ALK Inhibitors in Patients with ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series

Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer

Collaborators (9)

Gabriele Martelli

Tiziana Triulzi

Caterina Sposetti

Filippo Guglielmo Maria de Braud

Andrea Vingiani

Mattia Rediti

Kjersti Flatmark

Giovanni Fucà

Paolo Manca

Make your next move.